Dr Reddys Laboratories Ltd gained for a fifth straight session today. The stock is quoting at Rs 1287.7, up 0.02% on the day ...

Stay up-to-date with the Dr Reddys Stock Liveblog, your trusted source for real-time updates and thorough analysis of a ...

Dr. Reddy's Laboratories Ltd. closed 8.46% below its 52-week high of 1,420.20 rupees, which the company reached on August 21st.

Dr Reddy's Laboratories share price gained almost 3% in the morning trades on Thursday post Q1 results that were declared ...

Hyderabad: Dr. Reddy’s Laboratories Ltd has announced an investment of Rs 565.4 crore in its step-down wholly owned ...

Indian generic drugs maker Dr Reddy's Laboratories posted a narrow miss of quarterly profit expectations on Wednesday, as it ...

Dr. Reddy’s Laboratories Limited (NYSE:RDY) is one of the Best Indian Stocks to Buy for Next 5 Years. Dr. Reddy’s ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

The company is going to announce results for the quarter ended June 30th, 2025 on July 23, 2025 after the board meeting.

The focus has now shifted to Semaglutide, the GLP-1 agonist being pursued as a generic version of Ozempic/Wegovy.

DRL posted a 2 per cent YoY increase in PAT to Rs 1,417.8 crore for Q1 FY26, compared with Rs 1,392 crore in the year-ago ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...